Welcome to the Novel Format Conjugates Summit

Built with Genentech, AstraZeneca, Starpharma, Avidity, and Guardian Therapeutics, 80+ key leaders and decision makers converged to reimagine traditional ADCs and discuss their novel format technologies.

The inaugural Novel Format Conjugates Summit exclusively focused on the common challenges across early research and development of next generation Non-Traditional ‘ADCs’, or alternative format conjugates approaches for oncology and beyond. This meeting delved into the different technologies of these novel-format conjugates, exploring how conjugation chemistry is affected for different kinds of therapeutic modalities, and the impact an alternative format ADC has on targeting.

As we look to the future of drug development of novel conjugates, attendees heard the cutting-edge science accelerating the development of Bispecific ADCs, Radio-conjugates, ISACs, SMDCs, Probody conjugates, Liposomal drug conjugates, Oligonucleotide conjugates and many more.

Attendees engaged in cross-industry discussions and presentations from over 20 expert speakers across 3 unmissable days, and equipped themselves with the tools to develop novel format ADCs with an improved therapeutic potential - to meet the aim of bringing more drugs to patients of unmet needs.